07 Tessa Therapeutics’ Allogeneic, “Off-the-Shelf” CD30 Cell Therapy to be Featured... READ MORE May Tessa Therapeutics today announced that early clinical data from a Phase 1 dose-escalation study of ... 30 Tessa Therapeutics Announces Enrollment of 12 Patient Pilot Cohort in its Relaps... READ MORE April Tessa Therapeutics today announced enrollment of 12 patient Pilot cohort of its Phase 2 trial (NCT04... 10 Tessa Therapeutics Announces Successful Dosing of First Patient Cohort in Phase ... READ MORE February Tessa Therapeutics today announced the successful completion of dosing of the first patient cohort (... 18 Tessa Therapeutics Receives PRIME Designation from European Medicines Agency for... READ MORE January Tessa Therapeutics today announced that the European Medicines Agency (EMA) has granted PRiority MEd... 17 Tessa Therapeutics Appoints David McIntyre as Chief Financial Officer READ MORE December Mr. McIntyre brings over 25 years of global financial, operational and legal experience, including o... 06 Tessa Therapeutics Announces Results from Two Independent Phase 1/2 Trials of Au... READ MORE August Tessa Therapeutics today announced the publication of results in the Journal of Clinical Oncology fr... 04 Tessa Therapeutics Announces New Executive Leadership READ MORE May Tessa Therapeutics today announced that Jeffrey H. Buchalter will assume the role of Chief Executive... 27 Tessa Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RM... READ MORE February RMAT designation follows positive proof-of-concept data from two independent Phase I/II clinical stu... 19 Tessa Therapeutics to Open 90,000 Square Foot Commercial-Scale Cell Therapy Manu... READ MORE December State-of-the-art manufacturing facility will support clinical and commercial production of cell ther... 22 Tessa Therapeutics Establishes New Scientific Advisory Board READ MORE May Tessa Therapeutics has established a new Scientific Advisory Board (SAB) with the appointment of a t... 30 Tessa Therapeutics, in Collaboration with Baylor College of Medicine, Presents P... READ MORE April Tessa Therapeutics today announced ‘proof-of-concept’ data from the preclinical study of TT16, a fir... 28 Biopharma veteran, Jeffrey H. Buchalter is our newest independent board director READ MORE February Mr Buchalter brings over thirty years’ experience in the biopharmaceutical industry, with strong cor... 21 Distinguished breast cancer expert, Dr. George W. Sledge, Jr., M.D., joins our B... READ MORE December Tessa Therapeutics announced that Dr. George W. Sledge, Jr., M.D., Professor and Chief of Medical On...
